KNSA

Kiniksa Pharmaceuticals Internat…

42.01

0.76+1.83%

Closed18:24 01/02 EST

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE41.26/41.25

TODAY RANGE40.95-42.90

VOL709.36K

MARKET CAP3.18B

52 WEEK RANGE17.82-44.42

AVG VOL (3M)427.95K

% TURNOVER0.94%

TURNOVER0

P/E (TTM)93.70

% RANGE4.72%

EPS(TTM)0.4483

P/E(FORWARD)47.20

P/B5.92

BVPS7.10

DIVIDEND--

P/S7.20

BETA--

DIV YIELD0.00%

FREE FLOAT MKT CAP1.83B

SHARES OUTSTANDING75.80M

NEXT EARNINGS02/16-02/27

FREE FLOAT43.65M

LOT SIZE1

EX-DATE--

News

Press Releases

Financial Reports

Profile

TipRanks·12/22/2025 13:35
Kiniksa Pharmaceuticals (KNSA) Gets a Buy from Wedbush
Reuters·12/17/2025 21:39
Director Barry D. Quart Reports Disposal of Kiniksa Pharmaceuticals International plc Common Shares
TipRanks·12/17/2025 16:32
Kiniksa Advances KPL-387 Study for Recurrent Pericarditis: What Investors Should Know
Seeking Alpha·12/16/2025 14:19
Tracking Baker Brothers Portfolio - Q3 2025 Update
TipRanks·12/12/2025 11:47
Wells Fargo Reaffirms Their Buy Rating on Kiniksa Pharmaceuticals (KNSA)
Reuters·12/01/2025 21:37
Kiniksa COO Eben Tessari Reports Disposal of Common Shares
TipRanks·11/18/2025 14:26
Kiniksa Pharmaceuticals (KNSA) Receives a Buy from Jefferies
Reuters·10/30/2025 20:47
Kiniksa CFO Mark Ragosa Reports Sale of Common Shares
Seeking Alpha·10/30/2025 13:05
Kiniksa: How Category Ownership And Higher Duration Are Translating Into Operating Leverage
NASDAQ·10/30/2025 12:25
New Strong Sell Stocks for Oct. 30th
Dow Jones·10/29/2025 18:19
Kiniksa Pharmaceuticals Is Maintained at Buy by Goldman Sachs
Dow Jones·10/29/2025 18:19
Kiniksa Pharmaceuticals Price Target Raised to $55.00/Share From $45.00 by Goldman Sachs
TipRanks·10/29/2025 04:29
Kiniksa Pharmaceuticals Reports Strong Q3 2025 Growth
TipRanks·10/29/2025 00:23
Kiniksa Pharmaceuticals’ Earnings Call Highlights Growth and Optimism
TipRanks·10/28/2025 16:35
Kiniksa Pharmaceuticals: Strong Q3 Performance and Growth Potential Justify Buy Rating

Same Industry

Name/Symbol

Change%

Price

Kiniksa Pharmaceuticals International, plc

KNSA

+1.83%

42.01

McKesson

MCK

+0.38%

823.44

Biogen Inc

BIIB

+1.04%

177.82

Amgen Inc

AMGN

+0.10%

327.64

Shire

SHPG

0.00%

179.20

Bristol-Myers Squibb Company Celegne Contingent Value Rights

CELG-RT

+10.71%

0.0796

Lilly Eli & Co

LLY

+0.53%

Celgene

CELG

0.00%

108.24

Therapeuticsmd Inc

TXMD

+1.23%

1.65

Johnson & Johnson

JNJ

+0.19%

207.35

Abbvie Inc

ABBV

+0.36%

229.31

Zoetis Inc

ZTS

+0.08%

125.92

Gilead Sciences Inc

GILD

-0.93%

121.60

Novo-Nordisk A/S

NVO

+2.97%

52.39

Bristol-Myers Squibb Co

BMY

+0.28%

53.46

Alexion Pharms

ALXN

+1.70%

182.50

Pfizer

PFE

+1.12%

25.18

Sanofi FR

SNY

-0.47%

48.23

Sanofi FR

GCVRZ

0.00%

0.8711

Novartis

NVS

+0.49%

138.54

Dr Reddys Labs

RDY

-1.28%

13.86

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.